Biogen says it does not plan to seek marketing approval for its motor neurone disease treatment, Qalsody (tofersen), from the UK medicines regulator, the MHRA, because it would be unlikely to receive a positive reimbursement recommendation under the appraisal route chosen by NICE, England’s health technology assessment (HTA) institute.
No UK Approval Filing For Biogen's Tofersen Because Of NICE HTA Decision
England’s health technology assessment body, NICE, says it has suspended the appraisal process for the motor neurone disease treatment while it considers the next steps. No HTA submission for tofersen has been made in Scotland.
More from Europe
More from Geography
• By
Ascertaining the novelty and benefits of Makary’s new drug approval idea – along with what it would take to implement it – requires more clarity on the types of studies he envisions being used to grant and confirm “plausible mechanism’ approvals.
• By
Consumer and academic group comments on accelerated approval and confirmatory trial guidances say the proposed criteria for determining when a study is underway are too vague.
• By
While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.